| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e3d48fd308b1b1b589e58fbbfaed7ed3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_94b51d317764e2f4f1bbcb355b274c8b |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2840-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-13043
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2035-122
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2506-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-10043 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0637 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-86 |
| filingDate |
2021-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7adcc92ec04102549d0a7c26fc394f1d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ff8e4d45b5e102d198c8916f483b5580
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7d2f4762cf445a86ff7cd8c105d7a11e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d61f348d079485782fd0ebf5b7e7bb71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8ce06d88bfe6a3e990492869c816d826 |
| publicationDate |
2022-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2022008474-A1 |
| titleOfInvention |
Engineered regulatory t cells |
| abstract |
Cell therapy compositions comprising engineered human regulatory T cells (eTregs) characterized by ectopic overexpression of FOXP3 and Helios protein, produced via introduction of separate nucleic acid constructs respectively encoding FOXP3 and Helios (FOXP3+ Helios+ eTregs). Cell therapy compositions comprising mixed populations of CD4+ and CD8+ Treg cells each with ectopic overexpression of FOXP3 and Helios. Methods of making and use the same for therapies involving inflammation and/or a disorder of the immune system. |
| priorityDate |
2019-07-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |